RANI News and Press, Rani Therapeutics Holdings Inc. From 05/04/25

2025-05-04 18:48:27 ET Rani Therapeutics Holdings, Inc. (RANI) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.83%. The average open to low on the day of earnings was -5.84%. The avera...

2025-05-04 18:43:28 ET Rani Therapeutics Holdings, Inc. (RANI) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in RANI stock price following earnings has averaged ±3.05% , with a median o...

2025-03-31 19:15:27 ET Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Conference Call March 31, 2025, 4:30 pm ET Company Participants Kiki Patel - IR, Gilmartin Group Talat Imran - CEO Svai Sanford - CFO Conference Call Participants Annabel ...

2025-03-31 16:31:25 ET More on Rani Therapeutics Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics Financial information for Rani Therapeutics Read the full article on Seeking Alpha For further det...

- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced preclinical data demonstrating successful oral delivery of semaglutide via R...

Spire Global Inc. Class A (SPIR) is expected to report $-0.97 for Q4 2024 CaliberCos Inc. (CWD) is expected to report $-0.04 for Q4 2024 Progress Software Corporation (PRGS) is expected to report $0.79 for Q1 2025 Nuvve Holding Corp. (NVVE) is expected to report for quarter end 2024-1...

- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e – - Both groups demonstrated comparable weight loss with less variability observed ...

Nu Ride Inc. - Class A (NRDE) is expected to report for quarter end 2024-12-31 Dalrada Financial Corp. (DFCO) is expected to report for quarter end 2024-12-31 HilleVax Inc. (HLVX) is expected to report $-0.38 for Q4 2024 Chewy Inc. Class A (CHWY) is expected to report $0.03 for Q4 202...

SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release ...

Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2024-12-31 Worthington Steel Inc. (WS) is expected to report $0.67 for Q3 2025 General Mills Inc. (GIS) is expected to report $0.95 for Q3 2025 Talphera Inc. (TLPH) is expected to report for Q4 2024 Sensei Biot...